According to a Phase 2a clinical trial reported by Pneumonia Research News, a combination of Salvecin (AR-301) plus antibiotics treated ventilator-associated bacterial pneumonia (VAP) better than antibiotic monotherapy. The combo therapy also resulted in reduced use of ventilation.
Salvecin’s developer, Aridis Pharmaceuticals, presented the trial results at the American Society for Microbiology Congress in New Orleans, June 1-5. They covered the combo’s effectiveness against hospital-acquired bacterial pneumonia, or HAP, as well as VAP.
The trial dealt with the effectiveness and safety of Salvecin as an adjunctive, or add-on, therapy against severe pneumonia caused by the Staphylococcus aureus bacteria.
Eradication of S. aureus was higher in the combo group than in the placebo group. And VAP patients who received the Salvecin-antibiotics combo spent less time under ventilation at all dose levels tested than a placebo group that received antibiotics only.